BioStem Technologies Welcomes KPMG for Growth and Uplisting
BioStem Technologies Appoints KPMG as Independent Accountant
BioStem Technologies, Inc. (OTC: BSEM), a prominent MedTech firm specializing in placental-derived products for advanced wound care, has made a significant move by appointing KPMG LLP as its independent registered public accounting firm. This decision comes after the company decided to conclude its engagement with Marcum LLP, known now as CBIZ, Inc., effective October 22, 2025.
Brandon Poe, the Chief Financial Officer of BioStem, expressed gratitude for the support Marcum provided during the company’s rapid growth over the past two years. “We undertook a comprehensive search to find an audit firm that aligns with our long-term growth plans and capital markets strategy, especially as we prepare for our anticipated uplist to Nasdaq,” he stated. “KPMG emerged as the preferred choice because of its dedicated life sciences team, which brings extensive industry experience to the table. We are confident that KPMG will deliver the specialized expertise necessary as we advance our organization.”
Throughout the two most recent fiscal years leading to this transition and the interim period prior to Marcum's dismissal, the company faced no disagreements regarding accounting principles, practices, financial disclosures, or auditing procedures. A detailed disclosure can be accessed through the company’s announcement on October 27, 2025.
Plans for Nasdaq Uplisting
After successfully completing the audits for fiscal years 2024 and 2025, BioStem aims to move forward with its uplisting to the Nasdaq Capital Market. Chairman and CEO Jason Matuszewski emphasized the potential benefits of this transition, noting greater company visibility, improved stock liquidity, precise market valuation, and enhanced ability to attract top talent.
“We believe we have a clear path toward uplisting, and we are actively building a solid foundation for a listing on a national exchange,” Matuszewski remarked. “Welcoming KPMG is a vital step that will help facilitate our growth during this significant phase of our corporate evolution.”
About BioStem Technologies, Inc.
BioStem Technologies is a leading innovator concentrating on utilizing the natural capabilities of perinatal tissue. The company is dedicated to developing, manufacturing, and commercializing allografts for regenerative therapies through its proprietary BioREtain processing method. The BioREtain approach incorporates the latest regenerative medicine research to preserve tissue structure and maintain growth factors effectively.
The quality management system at BioStem Technologies has received accreditation from the American Association of Tissue Banks (AATB) and adheres to current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). The company boasts a diverse portfolio of renowned brands such as AmnioWrap2™, VENDAJE, VENDAJE AC, and VENDAJE OPTIC, all processed at its FDA registered and AATB accredited facility in Pompano Beach, Florida.
Contact Information
For further inquiries, please visit www.biostemtechnologies.com or reach out via email at info@biostemtech.com. You can also follow the company on social media for the latest updates.
Investor Relations:
Philip Trip Taylor, Gilmartin Group
E-Mail: ir@biostemtech.com
Frequently Asked Questions
What is the significance of KPMG's appointment for BioStem?
KPMG is expected to provide the specialized expertise necessary for BioStem’s growth and strategic initiatives, including its uplisting to Nasdaq.
Why did BioStem transition from Marcum LLP to KPMG?
The transition was part of a comprehensive search to align with a firm that supports the company's long-term growth and capital markets ambitions.
What are the benefits of BioStem's uplisting to Nasdaq?
The uplisting aims to enhance visibility, improve stock liquidity, provide market valuation clarity, and attract top-tier talent to the organization.
How does BioStem ensure the quality of its products?
BioStem adheres to strict regulatory standards, being accredited by the AATB and compliant with cGTP and cGMP guidelines to guarantee the quality of its placental allografts.
Where can I find more information about BioStem Technologies?
You can visit their official website at www.biostemtechnologies.com for more information on their products and company updates.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.